Global Immunosuppressant Drugs market as valued at US$13.529 billion in 2019. Increasing number of organ transplants worldwide is one of the major drivers of the global immunosuppressant drugs market. There has been a rising demand for transplants for various organs such as liver, pancreas, kidney, and lungs. According to the latest statistics of the Global Observatory on Donation and Transplantation statistics, 146,840 organs were transplanted annually in 2018, representing a rise of 5.6 percent from the previous year. Also, according to the findings of the World Health Organization (WHO), around 91,800 kidney transplant procedures, 30,800 liver transplants, and 6,200 lung transplants took place globally during the same year. Other factors that have led to a worldwide increase in demand for organ transplantation is the rising incomes, the spread of personal health insurance, better and advanced healthcare facilities, and ageing population. According to data from World Population Prospects: the 2019 Revision, aged population (65 years and above) outnumbered children population (under 5 years of age) globally for the first time in 2018. Also, the number of people aged 80 years and above is projected to triple by 2050 from 2018 figures. Governments and global organizations are making efforts to create more awareness about organ donation in order to reduce the organ shortage. As such, the rising number of organ donors will continue to drive up the number of organ transplant procedures, which in turn, will significantly propel the growth of the global immunosuppressant drugs market during the next five years. Furthermore, advancements in organ transplantation procedures will further encourage people to sign up for the procedure, thus positively impacting the global immunosuppressant drugs market growth.
The introduction of generic version of immunosuppressant drugs has further boosted the market growth. These generic versions have substantially reduced the overall cost of the transplant procedure. Since, individuals who receive organ transplants are required to take life-long immunosuppressive drugs to prevent rejection, the launch of various generic versions is bolstering the overall market growth. Lupin has recently launched generic immunosuppressant Tacrolimus capsules in the U.S. market after its alliance partner Concord Biotech Ltd received an approval for ANDA, its new drug application, from the U.S. Food and Drug Administration (USFDA).
Another major factor that is fueling the market growth of immunosuppressant drugs market globally is the growing prevalence of autoimmune diseases across the globe. According to the American Autoimmune Related Diseases Association (AARDA), it can take a person an average of five years and five doctors to get diagnosed with an autoimmune disorder. However, autoimmunity has become one of the most common diseases categories.
Key market players are adopting various growth strategies to capture a larger share in the global immunosuppressant drugs market and maintain their global market position. For example, GlaxoSmithKline PLC announced the approval of its newly developed intravenous (IV) formulation of Benlysta by the USFDA. High investments in R&D to develop advanced immunosuppressant drugs by global vendors will also contribute to the global market growth during the forecast period. For instance, Pfizer is developing a new immunosuppressive drug which is based on the inhibition of JAK3, an important enzyme in the immune system, to prevent transplant rejection. In December 2018, Veloxis Pharmaceuticals announced that the company has got the approval from the USFDA for a new indication for Envarsus XR (tacrolimus extended-release tablets) to prevent organ rejection in kidney transplant patients in combination with other immunosuppressants.
The global immunosuppressant drugs market has been segmented on the basis of drug class, application, distribution channel, and geography. By drug class, the global immunosuppressant drugs market has been classified as calcineurin inhibitors, mTOR inhibitor, antibodies, and others. On the basis of application, the market segmentation has been done as organ transplantation and autoimmune disorder. By distribution channel, the global immunosuppressant drugs market has been segmented as online and offline.
By geography, North America accounts for a significant share in the global immunosuppressant drugs market
Geographically, the global immunosuppressant drugs market has been segmented into five major regional markets- North America, South America, Europe, Middle East and Africa (MEA), and Asia Pacific (APAC). North America held the significant share in the global immunosuppressant drugs market in 2019. Advancements in technology and the presence of major market players in the region supports the growth of this regional market. Growing demand for organ transplants and procedures is boosting the demand for immunosuppressant drugs in countries like the United States and Canada, thereby driving the market growth. According to the U.S. government official data, 39,718 transplants were performed in 2019 in the country. Increasing awareness about organ donation is further paving the way for the rise in the number of transplant procedures which will boost the immunosuppressant drugs market growth during the next five years. 90 percent of U.S. adults support organ donation. Europe also accounts for a considerable market share throughout the forecast period. Rising prevalence of autoimmune diseases in the region coupled with investments in R&D contributes to the growth of the European immunosuppressant drugs market. In 2019, the project called Taxonomy, Treatments, Targets and Remission (3TR) was launched which is funded by the EU’s (European Union) Innovative Medicines Initiative for the next seven years. The project aims to discover biomarkers that can predict which patients will respond best to treatments for the following seven autoimmune conditions: inflammatory bowel disease, multiple sclerosis, asthma, systemic lupus erythematosus, rheumatoid arthritis, and chronic obstructive pulmonary disease. APAC and MEA will witness a substantial CAGR during the forecast period on account of rising number of organ transplant procedures, supported by booming medical tourism industry.
Market Players and Competitive Intelligence
Prominent key market players in the global Immunosuppressant Drugs market include Astellas Pharma Inc., Mylan N.V., Sanofi, AbbVie Inc., Veloxis Pharmaceuticals Inc., Pfizer Inc., GlaxoSmithKline plc, Dr. Reddy’s Laboratories Ltd., Lupin, F. Hoffmann-La Roche Ltd, and Swiss Pharma among others. These companies hold a noteworthy share in the market on account of their good brand image and product offerings. Major players in the global Immunosuppressant Drugs market have been covered along with their relative competitive position and strategies. The report also mentions recent deals and investments of different market players over the last two years.